Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2019 2
2020 1
2021 7
2022 10
2023 5
2024 11
2025 10
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean elagolix endometriosis (129 results)?
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Blair HA. Blair HA. Drugs. 2024 Apr;84(4):449-457. doi: 10.1007/s40265-024-02018-3. Epub 2024 Apr 9. Drugs. 2024. PMID: 38592603 Free PMC article. Review.
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree( ) (USA); Ryeqo( ) (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to sev …
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree( ) (USA); Ryeqo …
Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment.
Rolla E. Rolla E. F1000Res. 2019 Apr 23;8:F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019. F1000Res. 2019. PMID: 31069056 Free PMC article. Review.
Endometriosis is an enigmatic disease that could start at birth. Its pathogenesis is supported by different theories. ...Special reference will be made to the quality of surgery and how to understand patients with endometriosis and endometriosis....
Endometriosis is an enigmatic disease that could start at birth. Its pathogenesis is supported by different theories. ...Special refe …
Medical management of endometriosis.
Alonso A, Gunther K, Maheux-Lacroix S, Abbott J. Alonso A, et al. Curr Opin Obstet Gynecol. 2024 Oct 1;36(5):353-361. doi: 10.1097/GCO.0000000000000983. Epub 2024 Aug 17. Curr Opin Obstet Gynecol. 2024. PMID: 39159261 Free PMC article. Review.
This review summarizes recent evidence regarding various medical management options available to treat pelvic pain associated with endometriosis. RECENT FINDINGS: Efficacy of dienogest vs. combined oral contraceptive on pain associated with endometriosis: randomized …
This review summarizes recent evidence regarding various medical management options available to treat pelvic pain associated with endome …
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.
Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Harada T, et al. Fertil Steril. 2022 Mar;117(3):583-592. doi: 10.1016/j.fertnstert.2021.11.013. Epub 2021 Dec 8. Fertil Steril. 2022. PMID: 34895700 Free article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of 40-mg relugolix (REL) compared with those of leuprorelin (LEU) in women with endometriosis-associated pain. ...Discontinuations from treatment emergent adverse events were 2.9% for REL and 4.3% for LEU. CONCLUSION(S) …
OBJECTIVE: To evaluate the efficacy and safety of 40-mg relugolix (REL) compared with those of leuprorelin (LEU) in women with end …
Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes.
Xie J, Ni X, Huang Q, Guo Y. Xie J, et al. Front Endocrinol (Lausanne). 2025 Sep 29;16:1650579. doi: 10.3389/fendo.2025.1650579. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 41089279 Free PMC article.
METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating relugolix for endometriosis-associated pain, with a primary focus on HRQoL assessed by the Endometriosis Health Profile-30 (EHP-30). ...CONCLUSION …
METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating relugolix for end …
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y, Mathur V, Warsi QA, Wagman RB, Johnson NP. Giudice LC, et al. Lancet. 2022 Jun 18;399(10343):2267-2279. doi: 10.1016/S0140-6736(22)00622-5. Lancet. 2022. PMID: 35717987 Free article. Clinical Trial.
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was evaluated for treatment of endometriosis-associated pain. ...Women received (1:1:1) once-daily oral placebo, relugolix combination therapy ( …
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was evaluated for tre …
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Becker CM, Johnson NP, As-Sanie S, Arjona Ferreira JC, Abrao MS, Wilk K, Imm SJ, Mathur V, Perry JS, Wagman RB, Giudice LC. Becker CM, et al. Hum Reprod. 2024 Mar 1;39(3):526-537. doi: 10.1093/humrep/dead263. Hum Reprod. 2024. PMID: 38243752 Free PMC article. Clinical Trial.
STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? ...Two-year results were analysed by treatment group based on original rand …
STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in wom …
Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
As-Sanie S, Abrao MS, Reznichenko G, Wilk K, Zhong Y, Perry J, Hunsche E, Soulban G, Becker CM. As-Sanie S, et al. Fertil Steril. 2024 Oct;122(4):687-695. doi: 10.1016/j.fertnstert.2024.06.009. Epub 2024 Jun 19. Fertil Steril. 2024. PMID: 38906210 Free article. Clinical Trial.
Results up to 104 weeks are reported by a pivotal trial treatment group with a focus on the relugolix CT group (i.e., relugolix CT or placebo for 24 weeks, or delayed relugolix CT [relugolix 40 mg monotherapy for 12 weeks, followed by relugolix …
Results up to 104 weeks are reported by a pivotal trial treatment group with a focus on the relugolix CT group (i.e., relugolix …
48 results